N4 Pharma Plc
N4P.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £7 | £2 | £0 | £0 |
| % Growth | 272.9% | – | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £7 | £2 | £0 | £0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | £390 | £619 | £578 | £1,179 |
| G&A Expenses | £552 | £718 | £616 | £664 |
| SG&A Expenses | £838 | £718 | £616 | £664 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£61 | £90 | -£0 | £0 |
| Operating Expenses | £1,167 | £1,427 | £1,193 | £1,843 |
| Operating Income | -£1,221 | -£1,425 | -£1,193 | -£1,843 |
| % Margin | -16,767.4% | -72,964.7% | – | – |
| Other Income/Exp. Net | £0 | £0 | £0 | £1 |
| Pre-Tax Income | -£1,221 | -£1,425 | -£1,193 | -£1,843 |
| Tax Expense | -£101 | -£148 | -£164 | -£298 |
| Net Income | -£1,059 | -£1,269 | -£1,029 | -£1,544 |
| % Margin | -14,542.7% | -64,977% | – | – |
| EPS | -0.003 | -0.005 | -0.006 | -0.009 |
| % Growth | 40.4% | 5.5% | 35.3% | – |
| EPS Diluted | -0.003 | -0.005 | -0.006 | -0.009 |
| Weighted Avg Shares Out | 340,387 | 242,890 | 186,423 | 181,080 |
| Weighted Avg Shares Out Dil | 340,881 | 242,890 | 186,423 | 181,080 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £1 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £89 | £228 | £237 |
| EBITDA | -£1,221 | -£1,335 | -£1,193 | -£1,843 |
| % Margin | -16,767.4% | -68,356.4% | – | – |